Modifiable risk factors accounted for almost half of the global cancer mortality and disability-adjusted life–years in 2019, shows an analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study.

TERAVOLT registry investigators have identified seven major risk factors for COVID-19 mortality in patients with thoracic malignancy, with poor ECOG performance status the strongest prognostic marker.

The risk for osteonecrosis of the jaw following zoledronic acid treatment in patients with bone metastases is associated with cancer type, oral health, and dosing frequency, US researchers report.

Among patients with systemic lupus erythematosus, the risk for cancer may be increased in older patients, men, and those who smoke, suggests an analysis of data from an international cohort.

In multivariate analysis adjusting for risk factors, ARDS was a significant 21.4 times more likely to occur in patients who had bilateral pneumonia, who were in turn 32.8 times more likely to die than other patients.

Clinically significant pathogenic/likely pathogenic germline variants, particularly in DNA damage repair genes, are common in patients with advanced urothelial cancer according to sequencing data.

Certain patient groups generally considered at low risk for developing myocarditis may need careful monitoring if they are taking immune checkpoint inhibitors for cancer, say researchers.

There's a new home for news and congress coverage! Catch up on all the top stories and latest evidence in oncology research with our ESMO congress hub page.  Learn more »

An analysis of the CCC19 registry has demonstrated a significant link between receipt of anticancer therapies within 3 months of a COVID-19 diagnosis and an elevated risk for venous thromboembolism

In men with metastatic castration-resistant prostate cancer and seizure risk factors, treatment with enzalutamide does not increase the incidence of seizures, shows the UPWARD safety study.

Anthracycline exposure in young adults who previously received cancer treatment is associated with a significantly elevated risk for heart failure.

Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

Supplementing endocrine therapy with ribociclib significantly decreases the relapse risk in people with hormone receptor-positive, HER2-negative, early breast cancer.